NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Advaxis, Inc. (OTCBB: ADXS), the live, attenuated Listeria monocytogenes (Lm) immunotherapy company, will host an investigator’s meeting in Mumbai, India with twenty (20) of the country’s leading oncologists. The meeting is set for May 7-8, 2010 and will help prepare for the initiation of a multicenter study of their lead compound, ADXS11-001 for the treatment of advanced, metastatic cervix cancer in women who have failed cytotoxic therapy.
